Showing results (281-290 of 303) with videos related to

Sort By:
Pageof 31
FEBS Open Bio|December 28, 2013
Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organsFiona M Keane, Tsun-Wen Yao, Stefanie Seelk, et al.
Immunity|August 17, 2017
A Liver Capsular Network of Monocyte-Derived Macrophages Restricts Hepatic Dissemination of Intraperitoneal Bacteria by Neutrophil RecruitmentFrederic Sierro, Maximilien Evrard, Simone Rizzetto, et al.
The Journal of Infectious Diseases|September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling PathwaysSamuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 15, 2024
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapySimon J Hume, Danny K Wong, Man-Fung Yuen, et al.
Springerplus|September 3, 2016
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3Graham R Foster, Kazuaki Chayama, Wan-Long Chuang, et al.
Hepatology Communications|July 17, 2023
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participantsAlexander J Thompson, Kathy Jackson, Sara Bonanzinga, et al.
Gastroenterology|October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis BPatrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
The Lancet. Gastroenterology & Hepatology|May 22, 2026
The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729-001): a phase 1a/b trialMan-Fung Yuen, Edward Gane, Jacinta A Holmes, et al.
Hepatology International|August 24, 2021
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapyGeorge Lau, Ming-Lung Yu, Grace Wong, et al.
Cancers|December 23, 2023
Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie Ngu, et al.
Pageof 31